SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 0.00 |
Enterprise Value ($M) | 1.19 |
Book Value ($M) | -4.16 |
Book Value / Share | -270.54 |
Price / Book | -0.00 |
NCAV ($M) | -4.22 |
NCAV / Share | -274.48 |
Price / NCAV | -0.00 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | n/a |
Return on Assets (ROA) | -6.90 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.00 |
Current Ratio | 0.00 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 0.02 |
Assets | 0.08 |
Liabilities | 4.24 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -1.54 |
Net Income | -1.82 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -0.94 |
Cash from Investing | 0.00 |
Cash from Financing | 0.94 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) | ||
(click for more detail) |
Similar Companies | |
---|---|
PHMMF – Pharma Mar, S.A. | PKTX – ProtoKinetix, Incorporated |
PLPL – Plandaí Biotechnology, Inc. | PREDQ – Predictive Technology Group, Inc. |
PRNAF – Alterity Therapeutics Limited |
Financial data and stock pages provided by
Fintel.io